spironolactone has been researched along with Acne in 106 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effectiveness of oral spironolactone for acne vulgaris in adult women." | 9.69 | Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial. ( Eminton, Z; Francis, N; Griffiths, G; Lawrence, M; Layton, AM; Little, P; Muller, I; Nuttall, J; Permyakova, N; Pyne, S; Renz, S; Ridd, MJ; Sach, TH; Santer, M; Soulsby, I; Stuart, B; Thomas, K; Thomas, KS, 2023) |
| "Participants of the SAFA (Spironolactone for Adult Female Acne) trial were invited to take part in a qualitative semi-structured interview to explore their experience and perspectives of taking part in the trial." | 9.69 | Factors that influence women's enrolment and ongoing participation in a partially decentralised randomised controlled dermatology trial: a qualitative interview study with participants in the SAFA (Spironolactone for Adult Female Acne) trial. ( Boxall, C; Cluff, C; Eminton, Z; Layton, AM; Muller, I; Nuttall, J; Renz, S; Saji, A; Santer, M; Soulsby, I; Wilcox, C, 2023) |
| "Women (≥18 years) with persistent facial acne requiring systemic therapy are randomised to receive one tablet per day of 50 mg spironolactone or a matched placebo until week 6, increasing to up to two tablets per day (total of 100 mg spironolactone or matched placebo) until week 24, along with usual topical therapy if desired." | 9.41 | Spironolactone for adult female acne (SAFA): protocol for a double-blind, placebo-controlled, phase III randomised study of spironolactone as systemic therapy for acne in adult women. ( Chinnery, F; Day, L; Eminton, Z; Francis, N; Griffiths, G; Layton, AM; Little, P; Muller, I; Nuttall, J; Renz, S; Ridd, MJ; Sach, T; Santer, M; Soulsby, I; Stanton, L; Stuart, B; Thomas, K; Thomas, KS, 2021) |
| "Spironolactone (SP) known as an anti-androgen drug, has been proven to be effective in treatment of acne." | 9.22 | Spironolactone loaded nanostructured lipid carrier gel for effective treatment of mild and moderate acne vulgaris: A randomized, double-blind, prospective trial. ( Akbari, J; Akhtari, J; Asare-Addo, K; Hajheydari, Z; Kelidari, HR; Morteza-Semnani, K; Nokhodchi, A; Saeedi, M; Valizadeh, H, 2016) |
| "To compare the effects of ethinyl estradiol (EE) 30 mcg/desogestrel 150 mcg plus spironolactone 25 mg/day (group A) versus EE 35 mcg/cyproterone acetate 2 mg (group B) on hyperandrogenism and metabolism in PCOS." | 9.20 | Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial. ( Jongwutiwes, T; Leelaphiwat, S; Lertvikool, S; Rattanasiri, S; Sukprasert, M; Tabcharoen, C; Weerakiet, S, 2015) |
| "Topical spironolactone may be effective for the treatment of acne patients with increased sebum secretion." | 9.16 | Comparison of the efficacy of 5% topical spironolactone gel and placebo in the treatment of mild and moderate acne vulgaris: a randomized controlled trial. ( Afzali, BM; Bagherani, N; Dabbagh, MA; Yaghoobi, E; Yaghoobi, R, 2012) |
| "The effect of oral spironolactone (200 mg daily) on acne vulgaris has been studied in 21 women in a randomized, placebo-controlled, double-blind crossover study using 3 month treatment periods." | 9.06 | Oral spironolactone: an effective treatment for acne vulgaris in women. ( Carter, GD; Cream, JJ; Muhlemann, MF; Wise, P, 1986) |
| "In a consecutive series of thirty-six male and female patients referred with severe acne, the effect of 3 months' treatment with placebo or spironolactone (50-200 mg daily) on sebum excretion and clinical and endocrine status was evaluated double-blind." | 9.05 | Oral spironolactone improves acne vulgaris and reduces sebum excretion. ( Alaghband-Zadeh, J; Carter, G; Cream, JJ; Goodfellow, A; Holland, S; Scully, J; Wise, P, 1984) |
| "Our aim was to conduct a hybrid systematic review of the evidence for benefits and potential harms of oral spironolactone in the management of acne in adult females." | 8.95 | Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review. ( Del Rosso, JQ; Eady, EA; Fedorowicz, Z; Layton, AM; van Zuuren, EJ; Whitehouse, H, 2017) |
| "The objective was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women." | 8.85 | Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Brown, J; Farquhar, C; Jepson, RG; Lee, O; Toomath, R, 2009) |
| "The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women." | 8.82 | Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2003) |
| "The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women." | 8.81 | Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2001) |
| "The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women." | 8.80 | Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2000) |
| "Studies assessing the utility of spironolactone for treating acne in adolescent females are lacking." | 8.02 | Use of spironolactone to treat acne in adolescent females. ( Davis, DMR; Hand, JL; Nowsheen, S; Roberts, EE; Tollefson, MM; Wetter, DA, 2021) |
| "Although recent studies and guideline recommendations indicate that potassium level monitoring is of low usefulness for healthy young women being treated for acne with spironolactone, little is known about whether these recommendations have been implemented in clinical practice." | 8.02 | Temporal Trends and Clinician Variability in Potassium Monitoring of Healthy Young Women Treated for Acne With Spironolactone. ( Barbieri, JS; Margolis, DJ; Mostaghimi, A, 2021) |
| "There are limited data regarding the long-term outcomes of spironolactone use for women with acne and its effect on truncal acne." | 8.02 | Long-term use of spironolactone for acne in women: A case series of 403 patients. ( Barbieri, JS; Choi, JK; Garg, V; James, WD, 2021) |
| "Few large studies have assessed spironolactone treatment of adult female acne." | 7.96 | Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007-2017. ( Davis, MDP; McEvoy, MT; Newman, CC; Nowsheen, S; Roberts, EE; Sartori Valinotti, JC; Sciallis, GF; Torgerson, RR; Wetter, DA, 2020) |
| "Using the OptumInsight™ Clinformatics™ DataMart, we conducted a retrospective analysis of the frequency of switching to a different systemic agent within the first year of therapy among women with acne who were started on either spironolactone or an oral tetracycline-class antibiotic between 2010-2016, after controlling for age, topical retinoid, and oral contraceptive use." | 7.88 | Frequency of Treatment Switching for Spironolactone Compared to Oral Tetracycline-Class Antibiotics for Women With Acne: A Retrospective Cohort Study 2010-2016. ( Barbieri, JS; Choi, JK; Margolis, DJ; Mitra, N, 2018) |
| "Prior studies have demonstrated that spironolactone is an effective second-line treatment option for postadolescent acne, but has notable side effects." | 7.85 | Spironolactone for the Treatment of Acne: A 4-Year Retrospective Study. ( Alikhan, A; Grandhi, R, 2017) |
| "Spironolactone has been shown to be an effective treatment option for hormonally mediated acne but can cause hyperkalemia." | 7.81 | Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. ( Mostaghimi, A; Plovanich, M; Weng, QY, 2015) |
| "To access the efficacy of spironolactone and topical retinoids in the treatment of female cyclical acne." | 7.80 | Spironolactone and topical retinoids in adult female cyclical acne. ( Elliott, L; Fisher, S; Kobraei, K; Lessner, E; Lessner, R; Osleber, M; Wesson, S, 2014) |
| "In situations where acne has proved resistant to other systemic agents or they are not indicated and isotretinoin is not desired by patients, the authors find amoxicillin, TMP-SMX, and spironolactone, alone or in combination, useful alternatives." | 7.74 | The efficacy and safety of amoxicillin, trimethoprim-sulfamethoxazole, and spironolactone for treatment-resistant acne vulgaris. ( James, WD; Turowski, CB, 2007) |
| "We investigated the safety and efficacy of acne treatment using both spironolactone and a combined contraceptive containing drospirenone." | 7.74 | Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. ( Ciurea, A; Krunic, A; Scheman, A, 2008) |
| "Thirty-five consecutive patients with acne were treated with spironolactone 100 mg/day, 16 days each month for 3 months." | 7.73 | Effects and side-effects of spironolactone therapy in women with acne. ( Gorgulu, A; Piskin, S; Yemisci, A, 2005) |
| "The purpose of this study was to assess the therapeutic effect and tolerance of low doses of spironolactone used alone or as an adjunct in the treatment of acne in adult women." | 7.70 | Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. ( Shaw, JC, 2000) |
| "The antiandrogenic activity of spironolactone was used for treating hirsutism in 76 women, 29 of whom also had acne." | 7.68 | [Treatment of hirsutism with spironolactone and progestagen combination]. ( Dechaud, H; Elmidani, M; Garoscio-Cholet, M; Lejeune, H; Pugeat, M; Tourniaire, J, 1990) |
| "The authors report their clinical experience with topical treatment of seborrheic acne with a 5% spironolactone cream in 20 patients, 11 males and 9 females aged 12 to 28 years (average 20." | 7.68 | [Experience in the therapy of acne with topical administration of spironolactone as an antiandrogen]. ( Califano, L; Cannavò, S; Girardi, R; Siragusa, M, 1990) |
| "Spironolactone was not found to affect significant skin hydration, sebum, elasticity, melanin, and redness (p > 0." | 7.01 | Role of topical spironolactone in the treatment of acne: A systematic review of clinical trials-Does this therapy open a path towards favorable outcomes? ( Abbas, S; Ahmed, A; Eljack, MMF; Imran, L; Khan, Z; Kheljee, AZ; Munir, S; Rehan, ST; Tahir, MJ, 2023) |
| "Acne vulgaris has increased in women over the past 10 years; it currently affects 20-30% of women." | 6.94 | FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial. ( Beneton, N; Boisrobert, A; Chiffoleau, A; Claudel, JP; Corvec, S; Dert, C; Dréno, B; Flet, L; Hainaut, E; Khammari, A; Le Naour, S; Leccia, MT; Lemoigne, M; Machet, L; Nguyen, JM; Poinas, A; Riche, VP; Schirr-Bonnans, S; Vrignaud, F, 2020) |
| "Treatment with spironolactone aims to attenuate androgen-mediated conditions including acne, hidradenitis suppurativa, female pattern hair loss and hirsutism." | 6.66 | Spironolactone in dermatology: uses in acne and beyond. ( Al-Niaimi, F; Ali, FR; Searle, TN, 2020) |
| "Recognition that acne is an inflammatory condition, not an infectious one, has led to a call for reduction in antibiotic use, which has culminated in a re-evaluation of our nonantibiotic choices." | 6.61 | An Overview of Acne Therapy, Part 2: Hormonal Therapy and Isotretinoin. ( Baldwin, HE; Marson, JW, 2019) |
| "Participants of the SAFA (Spironolactone for Adult Female Acne) trial were invited to take part in a qualitative semi-structured interview to explore their experience and perspectives of taking part in the trial." | 5.69 | Factors that influence women's enrolment and ongoing participation in a partially decentralised randomised controlled dermatology trial: a qualitative interview study with participants in the SAFA (Spironolactone for Adult Female Acne) trial. ( Boxall, C; Cluff, C; Eminton, Z; Layton, AM; Muller, I; Nuttall, J; Renz, S; Saji, A; Santer, M; Soulsby, I; Wilcox, C, 2023) |
| "Spironolactone is an economical potassium-sparing diuretic with an anti-androgenic effect and a good safety profile." | 5.56 | Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism. ( Morgado-Carrasco, D; Vargas-Mora, P, 2020) |
| "Women (≥18 years) with persistent facial acne requiring systemic therapy are randomised to receive one tablet per day of 50 mg spironolactone or a matched placebo until week 6, increasing to up to two tablets per day (total of 100 mg spironolactone or matched placebo) until week 24, along with usual topical therapy if desired." | 5.41 | Spironolactone for adult female acne (SAFA): protocol for a double-blind, placebo-controlled, phase III randomised study of spironolactone as systemic therapy for acne in adult women. ( Chinnery, F; Day, L; Eminton, Z; Francis, N; Griffiths, G; Layton, AM; Little, P; Muller, I; Nuttall, J; Renz, S; Ridd, MJ; Sach, T; Santer, M; Soulsby, I; Stanton, L; Stuart, B; Thomas, K; Thomas, KS, 2021) |
| " The dosage of spironolactone applied was 4 mg/cm2 for 48 h." | 5.27 | Topical spironolactone inhibits dihydrotestosterone receptors in human sebaceous glands: an autoradiographic study in subjects with acne vulgaris. ( Berardesca, E; Borroni, G; Gabba, P; Rabbiosi, G; Ucci, G, 1988) |
| "While originally approved for the management of heart failure, hypertension, and edema, spironolactone is commonly used off label in the management of acne, hidradenitis, androgenetic alopecia, and hirsutism." | 5.22 | Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis. ( Barbieri, JS; Bommareddy, K; Hamade, H; Lopez-Olivo, MA; Tosh, T; Wehner, M, 2022) |
| "To compare the effects of ethinyl estradiol (EE) 30 mcg/desogestrel 150 mcg plus spironolactone 25 mg/day (group A) versus EE 35 mcg/cyproterone acetate 2 mg (group B) on hyperandrogenism and metabolism in PCOS." | 5.20 | Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial. ( Jongwutiwes, T; Leelaphiwat, S; Lertvikool, S; Rattanasiri, S; Sukprasert, M; Tabcharoen, C; Weerakiet, S, 2015) |
| " However, our recommendation against the use of combined oral contraceptive pills and in favor of spironolactone for the treatment of acne, in the setting of LE, received a satisfactory grading (grade A)." | 5.05 | The Safe Management of Acne Vulgaris in Lupus Erythematosus: A Systematic Review with Evidence-Based Treatment Recommendations. ( Forouzandeh, M; Maderal, AD, 2020) |
| "Our aim was to conduct a hybrid systematic review of the evidence for benefits and potential harms of oral spironolactone in the management of acne in adult females." | 4.95 | Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review. ( Del Rosso, JQ; Eady, EA; Fedorowicz, Z; Layton, AM; van Zuuren, EJ; Whitehouse, H, 2017) |
| "The objective was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women." | 4.85 | Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Brown, J; Farquhar, C; Jepson, RG; Lee, O; Toomath, R, 2009) |
| "English-language controlled clinical trials of systemic hormonal treatment of acne were sought by search of references of general dermatology texts, reviews on acne, drug product monographs, and computer-assisted search of MEDLINE, CINAHL, and COCHRANE databases between 1970 and 2003 using the key words hormonal, oral contraceptive, acne, spironolactone, cyproterone, flutamide, and therapy." | 4.82 | Hormonal treatment of acne: review of current best evidence. ( Tan, J, 2004) |
| "The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women." | 4.82 | Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2003) |
| "The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women." | 4.81 | Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2001) |
| "The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women." | 4.80 | Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2000) |
| "Although recent studies and guideline recommendations indicate that potassium level monitoring is of low usefulness for healthy young women being treated for acne with spironolactone, little is known about whether these recommendations have been implemented in clinical practice." | 4.02 | Temporal Trends and Clinician Variability in Potassium Monitoring of Healthy Young Women Treated for Acne With Spironolactone. ( Barbieri, JS; Margolis, DJ; Mostaghimi, A, 2021) |
| "There are limited data regarding the long-term outcomes of spironolactone use for women with acne and its effect on truncal acne." | 4.02 | Long-term use of spironolactone for acne in women: A case series of 403 patients. ( Barbieri, JS; Choi, JK; Garg, V; James, WD, 2021) |
| "Studies assessing the utility of spironolactone for treating acne in adolescent females are lacking." | 4.02 | Use of spironolactone to treat acne in adolescent females. ( Davis, DMR; Hand, JL; Nowsheen, S; Roberts, EE; Tollefson, MM; Wetter, DA, 2021) |
| "Few large studies have assessed spironolactone treatment of adult female acne." | 3.96 | Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007-2017. ( Davis, MDP; McEvoy, MT; Newman, CC; Nowsheen, S; Roberts, EE; Sartori Valinotti, JC; Sciallis, GF; Torgerson, RR; Wetter, DA, 2020) |
| "Using the OptumInsight™ Clinformatics™ DataMart, we conducted a retrospective analysis of the frequency of switching to a different systemic agent within the first year of therapy among women with acne who were started on either spironolactone or an oral tetracycline-class antibiotic between 2010-2016, after controlling for age, topical retinoid, and oral contraceptive use." | 3.88 | Frequency of Treatment Switching for Spironolactone Compared to Oral Tetracycline-Class Antibiotics for Women With Acne: A Retrospective Cohort Study 2010-2016. ( Barbieri, JS; Choi, JK; Margolis, DJ; Mitra, N, 2018) |
| "We performed a retrospective study at an academic medical center of female patients receiving HAAT (combined oral contraceptive [COC], spironolactone) for acne from January 2005 to October 2015." | 3.88 | The Use of Hormonal Antiandrogen Therapy in Female Patients with Acne: A 10-Year Retrospective Study. ( Bienenfeld, A; Nagler, AR; Orlow, SJ; Park, JH, 2018) |
| "Prior studies have demonstrated that spironolactone is an effective second-line treatment option for postadolescent acne, but has notable side effects." | 3.85 | Spironolactone for the Treatment of Acne: A 4-Year Retrospective Study. ( Alikhan, A; Grandhi, R, 2017) |
| "Spironolactone has been shown to be an effective treatment option for hormonally mediated acne but can cause hyperkalemia." | 3.81 | Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. ( Mostaghimi, A; Plovanich, M; Weng, QY, 2015) |
| "To access the efficacy of spironolactone and topical retinoids in the treatment of female cyclical acne." | 3.80 | Spironolactone and topical retinoids in adult female cyclical acne. ( Elliott, L; Fisher, S; Kobraei, K; Lessner, E; Lessner, R; Osleber, M; Wesson, S, 2014) |
| "We investigated the safety and efficacy of acne treatment using both spironolactone and a combined contraceptive containing drospirenone." | 3.74 | Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. ( Ciurea, A; Krunic, A; Scheman, A, 2008) |
| "In situations where acne has proved resistant to other systemic agents or they are not indicated and isotretinoin is not desired by patients, the authors find amoxicillin, TMP-SMX, and spironolactone, alone or in combination, useful alternatives." | 3.74 | The efficacy and safety of amoxicillin, trimethoprim-sulfamethoxazole, and spironolactone for treatment-resistant acne vulgaris. ( James, WD; Turowski, CB, 2007) |
| "Thirty-five consecutive patients with acne were treated with spironolactone 100 mg/day, 16 days each month for 3 months." | 3.73 | Effects and side-effects of spironolactone therapy in women with acne. ( Gorgulu, A; Piskin, S; Yemisci, A, 2005) |
| "The inhibitive components in anti-acne cosmetics including spironolactone, benzoyl peroxide, and tretinoin were simultaneously determined by reversed-phase high performance liquid chromatography (RP-HPLC)." | 3.73 | [Simultaneous determination of inhibitive components in anti-acne cosmetics by reversed-phase high performance liquid chromatography]. ( Li, N; Wang, C; Wu, T, 2006) |
| "The purpose of this study was to assess the therapeutic effect and tolerance of low doses of spironolactone used alone or as an adjunct in the treatment of acne in adult women." | 3.70 | Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. ( Shaw, JC, 2000) |
| "The antiandrogenic activity of spironolactone was used for treating hirsutism in 76 women, 29 of whom also had acne." | 3.68 | [Treatment of hirsutism with spironolactone and progestagen combination]. ( Dechaud, H; Elmidani, M; Garoscio-Cholet, M; Lejeune, H; Pugeat, M; Tourniaire, J, 1990) |
| "The authors report their clinical experience with topical treatment of seborrheic acne with a 5% spironolactone cream in 20 patients, 11 males and 9 females aged 12 to 28 years (average 20." | 3.68 | [Experience in the therapy of acne with topical administration of spironolactone as an antiandrogen]. ( Califano, L; Cannavò, S; Girardi, R; Siragusa, M, 1990) |
| "A survey of 54 patients taking spironolactone for hirsutes or acne showed that side-effects occurred in 91%; in 80% of patients, these were related to the anti-androgenic mechanism of the drug (menstrual disturbances, and breast enlargement and tenderness)." | 3.67 | Tolerance of spironolactone. ( Cunliffe, WJ; Hughes, BR, 1988) |
| "Spironolactone was not found to affect significant skin hydration, sebum, elasticity, melanin, and redness (p > 0." | 3.01 | Role of topical spironolactone in the treatment of acne: A systematic review of clinical trials-Does this therapy open a path towards favorable outcomes? ( Abbas, S; Ahmed, A; Eljack, MMF; Imran, L; Khan, Z; Kheljee, AZ; Munir, S; Rehan, ST; Tahir, MJ, 2023) |
| "Acne vulgaris has increased in women over the past 10 years; it currently affects 20-30% of women." | 2.94 | FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial. ( Beneton, N; Boisrobert, A; Chiffoleau, A; Claudel, JP; Corvec, S; Dert, C; Dréno, B; Flet, L; Hainaut, E; Khammari, A; Le Naour, S; Leccia, MT; Lemoigne, M; Machet, L; Nguyen, JM; Poinas, A; Riche, VP; Schirr-Bonnans, S; Vrignaud, F, 2020) |
| "Spironolactone is a drug, similar in structure to aldosterone and acts as an aldosterone receptor antagonist with an anti-androgenic effect." | 2.82 | Spironolactone in dermatology. ( Aguilar Medina, DA; Cazarín, J; Magaña, M, 2022) |
| "Acne vulgaris affects approximately 9% of the population worldwide and approximately 85% of those aged 12 to 24 years." | 2.72 | Management of Acne Vulgaris: A Review. ( Eichenfield, DZ; Eichenfield, LF; Sprague, J, 2021) |
| "Treatment with spironolactone aims to attenuate androgen-mediated conditions including acne, hidradenitis suppurativa, female pattern hair loss and hirsutism." | 2.66 | Spironolactone in dermatology: uses in acne and beyond. ( Al-Niaimi, F; Ali, FR; Searle, TN, 2020) |
| " Also it appears that individual differences in CPA bioavailability do not satisfactorily explain the lack of therapeutic response in about 30% of the cases." | 2.65 | Antiandrogens in the treatment of acne and hirsutism. ( Hammerstein, J; Moltz, L; Schwartz, U, 1983) |
| "Recognition that acne is an inflammatory condition, not an infectious one, has led to a call for reduction in antibiotic use, which has culminated in a re-evaluation of our nonantibiotic choices." | 2.61 | An Overview of Acne Therapy, Part 2: Hormonal Therapy and Isotretinoin. ( Baldwin, HE; Marson, JW, 2019) |
| "Acne is one of the most common diseases worldwide and affects ∼50 million individuals in the United States." | 2.61 | Approaches to limit systemic antibiotic use in acne: Systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments. ( Barbieri, JS; James, WD; Margolis, DJ; Spaccarelli, N, 2019) |
| "Current guidelines for the treatment of acne are based largely on expert consensus and advocate a combination of topical agents in mild to moderate cases and reserve the use of systemic therapies for moderate to severe or refractory cases of acne." | 2.55 | Modern management of acne. ( Cooper, AJ; Harris, VR, 2017) |
| "Acne vulgaris is a common reason why adult women present to dermatologists and can be a clinical challenge to treat." | 2.48 | Acne in the adult female patient: a practical approach. ( Kamangar, F; Shinkai, K, 2012) |
| "Because acne is a complex multifactorial disorder, combination treatment may be required to target its various pathogenic factors." | 2.44 | Tailoring individualized treatment plans for acne. ( Harper, JC, 2008) |
| "Acne affects more than 40 million people, of which more than half are women older than 25 years of age." | 2.44 | Hormonal therapy for acne. ( Clarke, S; George, R; Thiboutot, D, 2008) |
| "Hormonal aspects of acne are of particular interest in treating adult women." | 2.41 | Hormones and acne: pathophysiology, clinical evaluation, and therapies. ( Thiboutot, D, 2001) |
| "Acne is one of the commonest dermatological problems, experienced by approximately 80% of Western adolescents." | 2.41 | Acne. Myths and management issues. ( Clearihan, L, 2001) |
| " Such effects depend not only on increased androgen production by the ovary or adrenal gland but also on the bioavailability of androgen to peripheral tissues." | 2.37 | Anti-androgens in gynaecological practice. ( Franks, S; Reed, MJ, 1988) |
| "Acne is an off-label use of some COCs." | 1.72 | Female Pelvic Conditions: Polycystic Ovary Syndrome. ( Brady, PH; Gin, GT; Rosenblum, E; Wilkinson, LD, 2022) |
| "Spironolactone is an economical potassium-sparing diuretic with an anti-androgenic effect and a good safety profile." | 1.56 | Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism. ( Morgado-Carrasco, D; Vargas-Mora, P, 2020) |
| "Considerations for treating acne in adult women include childbearing potential, pregnancy, lactation, and concomitant skin conditions." | 1.48 | Treating Acne in Adult Women. ( Alexis, AF; Harper, JC; Stein Gold, LF; Tan, JKL, 2018) |
| "Cyproterone acetate has been used in Europe for many years, but in the United States it has only been approved as an orphan drug to treat severe hirsutism." | 1.28 | Antiandrogens in the treatment of acne and hirsutism. ( Jurzyk, RS; Rose, LI; Spielvogel, RL, 1992) |
| " We investigated the dose-response relationship for suppression of dehydroepiandrosterone sulfate (DHEAS) with the use of dexamethasone." | 1.28 | Treatment of androgenic disorders with dexamethasone: dose-response relationship for suppression of dehydroepiandrosterone sulfate. ( Bedocs, NM; Bergfeld, W; Gidwani, GP; Gupta, MK; Parker, R; Redmond, GP; Skibinski, C, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (15.09) | 18.7374 |
| 1990's | 11 (10.38) | 18.2507 |
| 2000's | 21 (19.81) | 29.6817 |
| 2010's | 26 (24.53) | 24.3611 |
| 2020's | 32 (30.19) | 2.80 |
| Authors | Studies |
|---|---|
| Eichenfield, DZ | 1 |
| Sprague, J | 1 |
| Eichenfield, LF | 1 |
| Horissian, M | 1 |
| Maczuga, S | 1 |
| Barbieri, JS | 12 |
| Zaenglein, AL | 2 |
| Aguilar Medina, DA | 1 |
| Cazarín, J | 1 |
| Magaña, M | 1 |
| Bommareddy, K | 1 |
| Hamade, H | 1 |
| Lopez-Olivo, MA | 1 |
| Wehner, M | 1 |
| Tosh, T | 1 |
| Wilkinson, LD | 1 |
| Brady, PH | 1 |
| Gin, GT | 1 |
| Rosenblum, E | 1 |
| Rehan, ST | 3 |
| Khan, Z | 3 |
| Abbas, S | 3 |
| Imran, L | 3 |
| Munir, S | 3 |
| Tahir, MJ | 3 |
| Kheljee, AZ | 3 |
| Eljack, MMF | 3 |
| Ahmed, A | 3 |
| Shields, A | 3 |
| Flood, K | 1 |
| Santer, M | 4 |
| Lawrence, M | 1 |
| Renz, S | 3 |
| Eminton, Z | 3 |
| Stuart, B | 2 |
| Sach, TH | 1 |
| Pyne, S | 1 |
| Ridd, MJ | 2 |
| Francis, N | 2 |
| Soulsby, I | 3 |
| Thomas, K | 2 |
| Permyakova, N | 1 |
| Little, P | 2 |
| Muller, I | 3 |
| Nuttall, J | 3 |
| Griffiths, G | 2 |
| Thomas, KS | 2 |
| Layton, AM | 5 |
| Layton, A | 1 |
| Boxall, C | 1 |
| Saji, A | 1 |
| Cluff, C | 1 |
| Wilcox, C | 2 |
| Basu, P | 1 |
| Elman, SA | 1 |
| Abudu, B | 1 |
| Beckles, A | 1 |
| Salian, P | 1 |
| Yanes, DA | 1 |
| Porter, ML | 1 |
| Reynolds, RV | 2 |
| Forouzandeh, M | 1 |
| Maderal, AD | 1 |
| Roberts, EE | 2 |
| Nowsheen, S | 2 |
| Davis, MDP | 1 |
| McEvoy, MT | 1 |
| Newman, CC | 1 |
| Sartori Valinotti, JC | 1 |
| Sciallis, GF | 1 |
| Torgerson, RR | 1 |
| Wetter, DA | 2 |
| Ragmanauskaite, L | 1 |
| Kahn, B | 1 |
| Ly, B | 1 |
| Yeung, H | 1 |
| Barker, RA | 1 |
| Thiboutot, D | 4 |
| Dréno, B | 4 |
| Sanders, V | 1 |
| Rueda, MJ | 1 |
| Gollnick, H | 1 |
| Guzman, AK | 1 |
| Vargas-Mora, P | 1 |
| Morgado-Carrasco, D | 1 |
| Poinas, A | 1 |
| Lemoigne, M | 1 |
| Le Naour, S | 1 |
| Nguyen, JM | 3 |
| Schirr-Bonnans, S | 1 |
| Riche, VP | 1 |
| Vrignaud, F | 1 |
| Machet, L | 1 |
| Claudel, JP | 1 |
| Leccia, MT | 1 |
| Hainaut, E | 1 |
| Beneton, N | 1 |
| Dert, C | 1 |
| Boisrobert, A | 1 |
| Flet, L | 1 |
| Chiffoleau, A | 1 |
| Corvec, S | 1 |
| Khammari, A | 3 |
| Searle, TN | 1 |
| Al-Niaimi, F | 1 |
| Ali, FR | 1 |
| Patiyasikunt, M | 1 |
| Chancheewa, B | 1 |
| Asawanonda, P | 1 |
| Noppakun, N | 1 |
| Kumtornrut, C | 1 |
| Patel, DJ | 1 |
| Bhatia, N | 1 |
| Davis, DMR | 1 |
| Hand, JL | 1 |
| Tollefson, MM | 1 |
| Berman, HS | 1 |
| Cheng, CE | 1 |
| Hogeling, M | 1 |
| Dhurat, R | 1 |
| Shukla, D | 1 |
| Lim, RK | 1 |
| Wambier, CG | 1 |
| Goren, A | 1 |
| Margolis, DJ | 5 |
| Garg, V | 1 |
| Choi, JK | 3 |
| James, WD | 4 |
| Mostaghimi, A | 2 |
| Chinnery, F | 1 |
| Day, L | 1 |
| Sach, T | 1 |
| Stanton, L | 1 |
| Grandhi, R | 1 |
| Alikhan, A | 1 |
| Isvy-Joubert, A | 1 |
| Gaultier, A | 1 |
| Saint-Jean, M | 2 |
| Le Moigne, M | 1 |
| Boisrobert, E | 1 |
| Park, JH | 1 |
| Bienenfeld, A | 2 |
| Orlow, SJ | 1 |
| Nagler, AR | 2 |
| Mitra, N | 1 |
| Harper, JC | 2 |
| Stein Gold, LF | 1 |
| Alexis, AF | 1 |
| Tan, JKL | 1 |
| Spaccarelli, N | 1 |
| Azarchi, S | 1 |
| Lo Sicco, K | 1 |
| Marchbein, S | 1 |
| Shapiro, J | 1 |
| Marson, JW | 1 |
| Baldwin, HE | 1 |
| Lessner, E | 1 |
| Fisher, S | 1 |
| Kobraei, K | 1 |
| Osleber, M | 1 |
| Lessner, R | 1 |
| Elliott, L | 1 |
| Wesson, S | 1 |
| Leelaphiwat, S | 1 |
| Jongwutiwes, T | 1 |
| Lertvikool, S | 1 |
| Tabcharoen, C | 1 |
| Sukprasert, M | 1 |
| Rattanasiri, S | 1 |
| Weerakiet, S | 1 |
| Buzney, E | 1 |
| Sheu, J | 1 |
| Buzney, C | 1 |
| Bettoli, V | 2 |
| Zauli, S | 1 |
| Virgili, A | 2 |
| Plovanich, M | 1 |
| Weng, QY | 1 |
| Graber, EM | 1 |
| Vary, JC | 1 |
| Friedman, AJ | 1 |
| Kelidari, HR | 1 |
| Saeedi, M | 1 |
| Hajheydari, Z | 1 |
| Akbari, J | 1 |
| Morteza-Semnani, K | 1 |
| Akhtari, J | 1 |
| Valizadeh, H | 1 |
| Asare-Addo, K | 1 |
| Nokhodchi, A | 1 |
| Hassoun, LA | 1 |
| Chahal, DS | 1 |
| Sivamani, RK | 1 |
| Larsen, LN | 1 |
| Cooper, AJ | 1 |
| Harris, VR | 1 |
| Eady, EA | 1 |
| Whitehouse, H | 1 |
| Del Rosso, JQ | 1 |
| Fedorowicz, Z | 1 |
| van Zuuren, EJ | 1 |
| George, R | 1 |
| Clarke, S | 1 |
| Brown, J | 1 |
| Farquhar, C | 4 |
| Lee, O | 4 |
| Toomath, R | 4 |
| Jepson, RG | 1 |
| Bergstrom, KG | 1 |
| Afzali, BM | 1 |
| Yaghoobi, E | 1 |
| Yaghoobi, R | 1 |
| Bagherani, N | 1 |
| Dabbagh, MA | 1 |
| Ballanger, F | 1 |
| Kamangar, F | 1 |
| Shinkai, K | 1 |
| Chen, W | 1 |
| Faure, M | 2 |
| Drapier-Faure, E | 2 |
| Jepson, R | 3 |
| Yemisci, A | 1 |
| Gorgulu, A | 1 |
| Piskin, S | 1 |
| Tan, J | 1 |
| Haroun, M | 1 |
| Lynde, CW | 1 |
| Wu, T | 1 |
| Wang, C | 1 |
| Li, N | 1 |
| Krunic, A | 1 |
| Ciurea, A | 1 |
| Scheman, A | 1 |
| Turowski, CB | 1 |
| Zaun, H | 1 |
| Hammerstein, J | 1 |
| Moltz, L | 1 |
| Schwartz, U | 1 |
| Goodfellow, A | 1 |
| Alaghband-Zadeh, J | 1 |
| Carter, G | 1 |
| Cream, JJ | 2 |
| Holland, S | 1 |
| Scully, J | 1 |
| Wise, P | 2 |
| Belaube, P | 1 |
| Devaux, J | 1 |
| Gamby, T | 1 |
| Garcin, G | 1 |
| Privat, Y | 1 |
| Vincenzi, C | 1 |
| Trevisi, P | 1 |
| Farina, P | 1 |
| Stinchi, C | 1 |
| Tosti, A | 1 |
| Corazza, M | 1 |
| Strumìa, R | 1 |
| Lombardi, AR | 1 |
| Schmidt, JB | 1 |
| Lubbos, HG | 1 |
| Hasinski, S | 1 |
| Rose, LI | 2 |
| Pollock, J | 1 |
| Sidbury, R | 1 |
| Paller, AS | 1 |
| Shaw, JC | 2 |
| Clearihan, L | 1 |
| Franz, R | 1 |
| Cunliffe, WJ | 4 |
| Jurzyk, RS | 1 |
| Spielvogel, RL | 1 |
| Redmond, GP | 1 |
| Gidwani, GP | 1 |
| Gupta, MK | 1 |
| Bedocs, NM | 1 |
| Parker, R | 1 |
| Skibinski, C | 1 |
| Bergfeld, W | 1 |
| Pugeat, M | 1 |
| Elmidani, M | 1 |
| Dechaud, H | 1 |
| Garoscio-Cholet, M | 1 |
| Lejeune, H | 1 |
| Tourniaire, J | 1 |
| Sciarra, F | 1 |
| Toscano, V | 1 |
| Concolino, G | 1 |
| Di Silverio, F | 1 |
| Califano, L | 1 |
| Cannavò, S | 1 |
| Siragusa, M | 1 |
| Girardi, R | 1 |
| Hatwal, A | 1 |
| Bhatt, RP | 1 |
| Agrawal, JK | 1 |
| Singh, G | 1 |
| Bajpai, HS | 1 |
| Walton, S | 1 |
| Lookingbill, P | 1 |
| Keczkes, K | 1 |
| Muhlemann, MF | 1 |
| Carter, GD | 1 |
| Verschoore, M | 1 |
| Pizzino, D | 1 |
| Varotti, C | 1 |
| Hughes, BR | 1 |
| Massone, L | 1 |
| Pestarino, A | 1 |
| Borghi, S | 1 |
| Berardesca, E | 1 |
| Gabba, P | 1 |
| Ucci, G | 1 |
| Borroni, G | 1 |
| Rabbiosi, G | 1 |
| Tomidei, M | 1 |
| Strani, G | 1 |
| Reed, MJ | 1 |
| Franks, S | 1 |
| Callan, AW | 1 |
| Burke, BM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Assessment of Clinical Trial Experiences of Patients With Acne[NCT05737758] | 500 participants (Anticipated) | Observational | 2024-03-31 | Not yet recruiting | |||
| Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman.[NCT03334682] | Phase 3 | 158 participants (Actual) | Interventional | 2018-01-31 | Completed | ||
| Vitamin D and Its Topical Analogues: A Possible Role in the Pathogenesis and Treatment of Acne Vulgaris[NCT03866447] | Phase 4 | 80 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | ||
| Topical Silymarin Cream Versus Salicylic Acid Peeling in Treatment of Acne Vulgaris: Split Face Study[NCT04490967] | Phase 4 | 30 participants (Anticipated) | Interventional | 2021-04-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
40 reviews available for spironolactone and Acne
| Article | Year |
|---|---|
Management of Acne Vulgaris: A Review.
Topics: Acne Vulgaris; Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Anti-Bacterial Ag | 2021 |
Spironolactone in dermatology.
Topics: Acne Vulgaris; Dermatology; Female; Hidradenitis Suppurativa; Hirsutism; Humans; Spironolactone | 2022 |
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.
Topics: Acne Vulgaris; Aged; Breast Neoplasms; Female; Hirsutism; Humans; Male; Middle Aged; Prostatic Neopl | 2022 |
Role of topical spironolactone in the treatment of acne: A systematic review of clinical trials-Does this therapy open a path towards favorable outcomes?
Topics: Acne Vulgaris; Clindamycin; Humans; Skin; Spironolactone | 2023 |
Role of topical spironolactone in the treatment of acne: A systematic review of clinical trials-Does this therapy open a path towards favorable outcomes?
Topics: Acne Vulgaris; Clindamycin; Humans; Skin; Spironolactone | 2023 |
Role of topical spironolactone in the treatment of acne: A systematic review of clinical trials-Does this therapy open a path towards favorable outcomes?
Topics: Acne Vulgaris; Clindamycin; Humans; Skin; Spironolactone | 2023 |
Role of topical spironolactone in the treatment of acne: A systematic review of clinical trials-Does this therapy open a path towards favorable outcomes?
Topics: Acne Vulgaris; Clindamycin; Humans; Skin; Spironolactone | 2023 |
Role of topical spironolactone in the treatment of acne: A systematic review of clinical trials-Does this therapy open a path towards favorable outcomes?
Topics: Acne Vulgaris; Clindamycin; Humans; Skin; Spironolactone | 2023 |
Role of topical spironolactone in the treatment of acne: A systematic review of clinical trials-Does this therapy open a path towards favorable outcomes?
Topics: Acne Vulgaris; Clindamycin; Humans; Skin; Spironolactone | 2023 |
Role of topical spironolactone in the treatment of acne: A systematic review of clinical trials-Does this therapy open a path towards favorable outcomes?
Topics: Acne Vulgaris; Clindamycin; Humans; Skin; Spironolactone | 2023 |
Role of topical spironolactone in the treatment of acne: A systematic review of clinical trials-Does this therapy open a path towards favorable outcomes?
Topics: Acne Vulgaris; Clindamycin; Humans; Skin; Spironolactone | 2023 |
Role of topical spironolactone in the treatment of acne: A systematic review of clinical trials-Does this therapy open a path towards favorable outcomes?
Topics: Acne Vulgaris; Clindamycin; Humans; Skin; Spironolactone | 2023 |
Spironolactone for acne in women.
Topics: Acne Vulgaris; England; Female; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2023 |
From Breakouts to Bargains: Strategies for Patient-Centered, Cost-effective Acne Care.
Topics: Acne Vulgaris; Adapalene; Benzoyl Peroxide; Cost-Benefit Analysis; Dermatologic Agents; Drug Combina | 2023 |
The Safe Management of Acne Vulgaris in Lupus Erythematosus: A Systematic Review with Evidence-Based Treatment Recommendations.
Topics: Acne Vulgaris; Contraceptives, Oral, Combined; Dermatologic Agents; Humans; Lupus Erythematosus, Sys | 2020 |
Acne and the Lesbian, Gay, Bisexual, or Transgender Teenager.
Topics: Abnormalities, Drug-Induced; Acne Vulgaris; Adolescent; Androgen Antagonists; Androgens; Contracepti | 2020 |
Oral Spironolactone for Acne Vulgaris in Adult Females: An Update of the Literature.
Topics: Acne Vulgaris; Administration, Oral; Adult; Clinical Trials as Topic; Female; Humans; Mineralocortic | 2020 |
Spironolactone in dermatology: uses in acne and beyond.
Topics: Acne Vulgaris; Adult; Alopecia; Dermatology; Drug Monitoring; Female; Hidradenitis Suppurativa; Hirs | 2020 |
Oral Antibiotics for Acne.
Topics: Acne Vulgaris; Administration, Oral; Anti-Bacterial Agents; Contraceptives, Oral; Dermatology; Drug | 2021 |
Acne Vulgaris.
Topics: Acne Vulgaris; Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Anti-Infective Ag | 2018 |
Approaches to limit systemic antibiotic use in acne: Systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Adult; Anti-Bacterial Agents; Diet, Pr | 2019 |
Androgens in women: Hormone-modulating therapies for skin disease.
Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Adrenal Hyperplasia, Congenital; Alopecia; Androgen Ant | 2019 |
An Overview of Acne Therapy, Part 2: Hormonal Therapy and Isotretinoin.
Topics: Acne Vulgaris; Contraceptives, Oral, Hormonal; Dermatologic Agents; Humans; Isotretinoin; Mineraloco | 2019 |
Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment.
Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Alopecia; Androgen Antagonists; Contraceptives, Oral, C | 2014 |
Is hormonal treatment still an option in acne today?
Topics: Acne Vulgaris; Adrenal Cortex Hormones; Adult; Androgen Antagonists; Contraceptives, Oral, Hormonal; | 2015 |
Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis.
Topics: Acetylcholine Release Inhibitors; Acne Vulgaris; Algorithms; Alopecia; Anti-Bacterial Agents; Antipe | 2015 |
The use of hormonal agents in the treatment of acne.
Topics: Acne Vulgaris; Administration, Oral; Contraceptive Agents; Cortodoxone; Cyproterone Acetate; Dermato | 2016 |
Modern management of acne.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Androgen Antagonists; Anti-Bacterial A | 2017 |
Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review.
Topics: Acne Vulgaris; Administration, Oral; Adult; Androgens; Anti-Bacterial Agents; Contraceptives, Oral, | 2017 |
Hormonal therapy for acne.
Topics: Acne Vulgaris; Androgen Antagonists; Contraceptives, Oral; Cyproterone Acetate; Female; Flutamide; H | 2008 |
Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
Topics: Acne Vulgaris; Androgen Antagonists; Drug Therapy, Combination; Female; Hirsutism; Humans; Randomize | 2009 |
Acne in the adult female patient: a practical approach.
Topics: Acne Vulgaris; Adolescent; Adult; Androgen Antagonists; Contraceptives, Oral, Hormonal; Dermatologic | 2012 |
Update and future of hormonal therapy in acne.
Topics: Acne Vulgaris; Androgen Antagonists; Androgens; Contraceptives, Oral, Hormonal; Dehydroepiandrostero | 2003 |
[Hormonal treatments of acne].
Topics: Acne Vulgaris; Androgen Antagonists; Cyproterone Acetate; Estrogens; Glucocorticoids; Humans; Minera | 2003 |
Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
Topics: Acne Vulgaris; Drug Therapy, Combination; Female; Glucocorticoids; Hirsutism; Humans; Male; Mineralo | 2003 |
Hormonal treatment of acne: review of current best evidence.
Topics: Acne Vulgaris; Androgen Antagonists; Contraceptives, Oral, Hormonal; Female; Flutamide; Humans; Male | 2004 |
Hormonal therapy of acne.
Topics: Acne Vulgaris; Adult; Androgen Antagonists; Androgens; Contraceptives, Oral, Hormonal; Cyproterone A | 2004 |
Tailoring individualized treatment plans for acne.
Topics: Acne Vulgaris; Adult; Anti-Bacterial Agents; Contraceptives, Oral; Contraindications; Drug Interacti | 2008 |
Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
Topics: Acne Vulgaris; Drug Therapy, Combination; Female; Glucocorticoids; Hirsutism; Humans; Male; Mineralo | 2000 |
The diagnosis and management of acne.
Topics: Acne Vulgaris; Administration, Topical; Anti-Bacterial Agents; Doxycycline; Estrogens; Female; Human | 2000 |
[What is the role of hormonal treatments in acne?].
Topics: Acne Vulgaris; Androgen Antagonists; Cyproterone; Estrogens; Flutamide; Glucocorticoids; Hormone Ant | 2001 |
Hormones and acne: pathophysiology, clinical evaluation, and therapies.
Topics: Acne Vulgaris; Androgens; Contraceptives, Oral, Hormonal; Drug Therapy, Combination; Estrogens; Fema | 2001 |
Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
Topics: Acne Vulgaris; Drug Therapy, Combination; Female; Glucocorticoids; Hirsutism; Humans; Male; Mineralo | 2001 |
Acne. Myths and management issues.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Adolescent; Adult; Anti-Bacterial Agen | 2001 |
Spironolactone in dermatologic therapy.
Topics: Acne Vulgaris; Animals; Endocrine Glands; Hirsutism; Humans; Skin Diseases; Spironolactone | 1991 |
[Hormonal aspects of acne].
Topics: Acne Vulgaris; Adolescent; Adrenal Cortex Hormones; Adult; Androgen Antagonists; Androgens; Child; C | 1987 |
Anti-androgens in gynaecological practice.
Topics: Acne Vulgaris; Androgen Antagonists; Androgens; Cyproterone; Female; Hirsutism; Humans; Spironolacto | 1988 |
Spironolactone therapy in hirsutism and acne.
Topics: Acne Vulgaris; Androgens; Drug Administration Schedule; Female; Hirsutism; Humans; Recurrence; Spiro | 1988 |
14 trials available for spironolactone and Acne
| Article | Year |
|---|---|
Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial.
Topics: Acne Vulgaris; Adult; Anti-Bacterial Agents; Double-Blind Method; Female; Humans; Immunoglobulin A; | 2023 |
Factors that influence women's enrolment and ongoing participation in a partially decentralised randomised controlled dermatology trial: a qualitative interview study with participants in the SAFA (Spironolactone for Adult Female Acne) trial.
Topics: Acne Vulgaris; Adolescent; Adult; Dermatology; Emotions; Female; Humans; Qualitative Research; Spiro | 2023 |
FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial.
Topics: Acne Vulgaris; Administration, Cutaneous; Adult; Clinical Trials, Phase III as Topic; Double-Blind M | 2020 |
Efficacy and tolerability of low-dose spironolactone and topical benzoyl peroxide in adult female acne: A randomized, double-blind, placebo-controlled trial.
Topics: Acne Vulgaris; Administration, Cutaneous; Adult; Benzoyl Peroxide; Dermatologic Agents; Double-Blind | 2020 |
Spironolactone for adult female acne (SAFA): protocol for a double-blind, placebo-controlled, phase III randomised study of spironolactone as systemic therapy for acne in adult women.
Topics: Acne Vulgaris; Adult; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Humans; Qual | 2021 |
Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
Topics: Acne Vulgaris; Adult; Androgen Antagonists; Androgens; Androstenedione; Cholesterol; Contraceptives, | 2015 |
Spironolactone loaded nanostructured lipid carrier gel for effective treatment of mild and moderate acne vulgaris: A randomized, double-blind, prospective trial.
Topics: Acne Vulgaris; Administration, Cutaneous; Adult; Double-Blind Method; Female; Gels; Humans; Lipids; | 2016 |
Comparison of the efficacy of 5% topical spironolactone gel and placebo in the treatment of mild and moderate acne vulgaris: a randomized controlled trial.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Double-Blind Method; Gels; Humans; Mine | 2012 |
Antiandrogens in the treatment of acne and hirsutism.
Topics: Acne Vulgaris; Androgen Antagonists; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Dru | 1983 |
Oral spironolactone improves acne vulgaris and reduces sebum excretion.
Topics: Acne Vulgaris; Adolescent; Adult; Androgens; Clinical Trials as Topic; Double-Blind Method; Drug Adm | 1984 |
Antiandrogens: clinical applications.
Topics: Acne Vulgaris; Adult; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Dermatitis, Seborrheic | 1990 |
Spironolactone and cimetidine in treatment of acne.
Topics: Acne Vulgaris; Adolescent; Adult; Cimetidine; Female; Humans; Male; Random Allocation; Spironolacton | 1988 |
Lack of effect of topical spironolactone on sebum excretion.
Topics: Acne Vulgaris; Administration, Topical; Female; Humans; Male; Sebum; Spironolactone | 1986 |
Oral spironolactone: an effective treatment for acne vulgaris in women.
Topics: Acne Vulgaris; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Random Allocation; Sex | 1986 |
52 other studies available for spironolactone and Acne
| Article | Year |
|---|---|
Trends in the prescribing pattern of spironolactone for acne and hidradenitis suppurativa in adolescents.
Topics: Acne Vulgaris; Adolescent; Hidradenitis Suppurativa; Humans; Spironolactone | 2022 |
Female Pelvic Conditions: Polycystic Ovary Syndrome.
Topics: Acne Vulgaris; Anovulation; Female; Finasteride; Gonadotropin-Releasing Hormone; Hirsutism; Humans; | 2022 |
Spironolactone use for acne is not associated with an increased risk of venous thromboembolism: A matched, retrospective cohort study.
Topics: Acne Vulgaris; Humans; Pulmonary Embolism; Retrospective Studies; Risk Factors; Spironolactone; Veno | 2023 |
What do we know about prescribing spironolactone for acne?
Topics: Acne Vulgaris; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2023 |
Effectiveness of spironolactone for women with acne vulgaris (SAFA) trial: a critically appraised topic.
Topics: Acne Vulgaris; Drug Therapy, Combination; Female; Humans; Spironolactone | 2023 |
High-dose spironolactone for acne in patients with polycystic ovarian syndrome: A single-institution retrospective study.
Topics: Acne Vulgaris; Female; Hirsutism; Humans; Mineralocorticoid Receptor Antagonists; Polycystic Ovary S | 2021 |
Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007-2017.
Topics: Acne Vulgaris; Adult; Female; Humans; Minnesota; Retrospective Studies; Spironolactone; Treatment Ou | 2020 |
Changes in the management of acne: 2009-2019.
Topics: Acne Vulgaris; Anti-Bacterial Agents; Antimicrobial Stewardship; Benzoyl Peroxide; Contraceptives, O | 2020 |
Comparative analysis of prescribing patterns of tetracycline class antibiotics and spironolactone between advanced practice providers and physicians in the treatment of acne vulgaris.
Topics: Acne Vulgaris; Anti-Bacterial Agents; Dermatologists; Drug Therapy, Combination; Humans; Mineralocor | 2021 |
Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism.
Topics: Acne Vulgaris; Alopecia; Dermatology; Female; Hidradenitis Suppurativa; Hirsutism; Humans; Spironola | 2020 |
Use of spironolactone to treat acne in adolescent females.
Topics: Acne Vulgaris; Adolescent; Adult; Child; Female; Humans; Minnesota; Retrospective Studies; Spironola | 2021 |
Spironolactone in the treatment of adolescent acne: A retrospective review.
Topics: Acne Vulgaris; Adolescent; Female; Humans; Retrospective Studies; Spironolactone; Treatment Outcome | 2021 |
Spironolactone in adolescent acne vulgaris.
Topics: Acne Vulgaris; Adolescent; Adult; Female; Humans; Hyperandrogenism; Mineralocorticoid Receptor Antag | 2021 |
Optimizing the Trial Design for a Comparative Effectiveness Study of Spironolactone versus Oral Antibiotics for Women With Acne: A Delphi Consensus Panel.
Topics: Acne Vulgaris; Administration, Oral; Adult; Anti-Bacterial Agents; Consensus; Delphi Technique; Fema | 2020 |
Long-term use of spironolactone for acne in women: A case series of 403 patients.
Topics: Acne Vulgaris; Administration, Oral; Adult; Contraceptives, Oral, Combined; Drug Therapy, Combinatio | 2021 |
Temporal Trends and Clinician Variability in Potassium Monitoring of Healthy Young Women Treated for Acne With Spironolactone.
Topics: Acne Vulgaris; Adolescent; Adult; Child; Cohort Studies; Databases, Factual; Drug Monitoring; Female | 2021 |
Spironolactone for the Treatment of Acne: A 4-Year Retrospective Study.
Topics: Acne Vulgaris; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Retrospective Studies; | 2017 |
Adult female acne treated with spironolactone: a retrospective data review of 70 cases.
Topics: Acne Vulgaris; Adult; Androgen Receptor Antagonists; Back; Contraceptives, Oral; Dermatitis, Seborrh | 2017 |
The Use of Hormonal Antiandrogen Therapy in Female Patients with Acne: A 10-Year Retrospective Study.
Topics: Acne Vulgaris; Adolescent; Adult; Androgen Antagonists; Anti-Bacterial Agents; Contraceptives, Oral, | 2018 |
Frequency of Treatment Switching for Spironolactone Compared to Oral Tetracycline-Class Antibiotics for Women With Acne: A Retrospective Cohort Study 2010-2016.
Topics: Acne Vulgaris; Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Cohort Studies; Drug | 2018 |
Treating Acne in Adult Women.
Topics: Acne Vulgaris; Adult; Contraceptives, Oral, Combined; Contraindications, Drug; Dermatologic Agents; | 2018 |
Real-world drug usage survival of spironolactone versus oral antibiotics for the management of female patients with acne.
Topics: Acne Vulgaris; Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Child; Drug Utilizati | 2019 |
Spironolactone and topical retinoids in adult female cyclical acne.
Topics: Acne Vulgaris; Adapalene; Administration, Cutaneous; Adult; Dermatologic Agents; Dose-Response Relat | 2014 |
Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne.
Topics: Acne Vulgaris; Adolescent; Adult; Female; Humans; Hyperkalemia; Middle Aged; Mineralocorticoid Recep | 2015 |
K+larity for Spironolactone: At Last!
Topics: Acne Vulgaris; Female; Humans; Hyperkalemia; Monitoring, Physiologic; Potassium; Spironolactone | 2015 |
Spironolactone for
Adult Female Acne.
Topics: Acne Vulgaris; Adult; Female; Humans; Menstrual Cycle; Mineralocorticoid Receptor Antagonists; Polyc | 2015 |
Everything old is new again: spironolactone and metformin in the treatment of acne.
Topics: Acne Vulgaris; Clinical Trials as Topic; Dermatologic Agents; Humans; Hypoglycemic Agents; Metformin | 2010 |
Importance of spironolactone in the treatment of acne in adult women.
Topics: Acne Vulgaris; Adult; Female; Humans; Spironolactone | 2011 |
Effects and side-effects of spironolactone therapy in women with acne.
Topics: Acne Vulgaris; Adult; Androgen Receptor Antagonists; Case-Control Studies; Dehydroepiandrosterone Su | 2005 |
Hormonal approach to the treatment of acne a Canadian perspective.
Topics: Acne Vulgaris; Adolescent; Adult; Androgen Antagonists; Canada; Child; Contraceptives, Oral, Hormona | 2004 |
[Simultaneous determination of inhibitive components in anti-acne cosmetics by reversed-phase high performance liquid chromatography].
Topics: Acne Vulgaris; Benzoyl Peroxide; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase | 2006 |
Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone.
Topics: Acne Vulgaris; Adult; Androgen Receptor Antagonists; Androstenes; Contraceptives, Oral, Combined; Et | 2008 |
The efficacy and safety of amoxicillin, trimethoprim-sulfamethoxazole, and spironolactone for treatment-resistant acne vulgaris.
Topics: Acne Vulgaris; Administration, Oral; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Drug The | 2007 |
[Indications and limits of anti-androgen therapy].
Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Chlormadinone Acetate; Cyproterone; Cyproterone Aceta | 1984 |
[Hormonotherapy in acute, idiopathic hirsutism, and seborrheic alopecia (author's transl)].
Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Androgens; Cyproterone; Dermatitis, Seborrheic; Estro | 1982 |
Facial contact dermatitis due to spironolactone in an anti-acne cream.
Topics: Acne Vulgaris; Administration, Cutaneous; Adult; Dermatitis, Contact; Drug Eruptions; Facial Dermato | 1993 |
Allergic contact dermatitis from spironolactone.
Topics: Acne Vulgaris; Acute Disease; Administration, Topical; Adult; Dermatitis, Allergic Contact; Drug Eru | 1996 |
Other antiandrogens.
Topics: Acne Vulgaris; Androgen Antagonists; Cimetidine; Female; Finasteride; Flutamide; Humans; Isotretinoi | 1998 |
Adverse effects of spironolactone therapy in women with acne.
Topics: Acne Vulgaris; Adolescent; Adult; Female; Humans; Mineralocorticoid Receptor Antagonists; Prospectiv | 1998 |
Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients.
Topics: Acne Vulgaris; Adolescent; Adult; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Min | 2000 |
Acne news.
Topics: Acne Vulgaris; Adult; Contraceptives, Oral, Hormonal; Female; Hormones; Humans; Isotretinoin; Spiron | 2001 |
Spironolactone in dermatology.
Topics: Acne Vulgaris; Female; Hirsutism; Humans; Spironolactone | 1992 |
Antiandrogens in the treatment of acne and hirsutism.
Topics: Acne Vulgaris; Cyproterone; Hirsutism; Humans; Spironolactone | 1992 |
Treatment of androgenic disorders with dexamethasone: dose-response relationship for suppression of dehydroepiandrosterone sulfate.
Topics: Acne Vulgaris; Adolescent; Adult; Alopecia; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1990 |
[Treatment of hirsutism with spironolactone and progestagen combination].
Topics: Acne Vulgaris; Adolescent; Adult; Drug Therapy, Combination; Female; Hirsutism; Humans; Norprogester | 1990 |
[Experience in the therapy of acne with topical administration of spironolactone as an antiandrogen].
Topics: Acne Vulgaris; Adolescent; Adult; Child; Drug Tolerance; Female; Humans; Male; Ointments; Spironolac | 1990 |
[Treatment of acne with antiandrogens: validity of treatment with spironolactone].
Topics: Acne Vulgaris; Drug Evaluation; Female; Humans; Male; Spironolactone | 1987 |
Tolerance of spironolactone.
Topics: Acne Vulgaris; Adult; Androgen Antagonists; Contraceptives, Oral; Drug Tolerance; Female; Hirsutism; | 1988 |
[Topical treatment of acne with spironolactone].
Topics: Acne Vulgaris; Adolescent; Adult; Drug Evaluation; Female; Humans; Ointments; Spironolactone; Time F | 1987 |
Topical spironolactone inhibits dihydrotestosterone receptors in human sebaceous glands: an autoradiographic study in subjects with acne vulgaris.
Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Autoradiography; Humans; Male; Receptors, | 1988 |
[Spironolactone administered topically in the treatment of acne].
Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Drug Evaluation; Drug Tolerance; Female; | 1987 |
Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia.
Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Female; Hirsutism; Humans; Spironolactone | 1985 |